This inventor holds 1 USPTO granted patent. Top assignees: Massachusetts Institute of Technology, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 8,586 
1 out of 3,696 
Years Active: 2022
Title: Helena dePuig Guixe: Innovator in Dengue Virus Detection
Introduction
Helena dePuig Guixe is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of biomedical research, particularly in the detection of dengue virus serotypes. Her innovative work has led to the development of a patented technology that enhances diagnostic capabilities for dengue virus infections.
Latest Patents
Helena holds a patent for "Anti-dengue virus NS1 protein monoclonal antibodies." This invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in biological samples. Each matched antibody pair is designed to detect only one serotype of dengue virus NS1 protein, ensuring specificity and reducing cross-reactivity with other serotypes. The technology facilitates the development of confirmatory in vitro diagnostic tests, such as sandwich immunoassays, which can distinguish the presence of dengue virus serotypes in samples derived from human subjects. Additionally, the invention includes kits comprising the matched antibody pairs and methods for their use in immunoassays. Helena's work also encompasses therapeutic compositions and methods for treating dengue virus infections.
Career Highlights
Helena has worked with prestigious institutions, including the Massachusetts Institute of Technology and the National Institutes of Health, a component of the US Department of Health & Human Services. Her experience in these organizations has significantly contributed to her expertise in the field of infectious diseases and diagnostics.
Collaborations
Helena has collaborated with notable colleagues, including Irene Bosch and Kimberly Hamad-Schifferli. These partnerships have further enriched her research and development efforts in the biomedical field.
Conclusion
Helena dePuig Guixe is a trailblazer in the fight against dengue virus infections through her innovative patent for monoclonal antibodies. Her contributions to biomedical research and diagnostics are invaluable and continue to impact public health positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile